In a B-ALL mouse model, the combination of acalabrutinib and CD19 CAR T cells prolonged the durability of CAR T cells in vivo and improved the survival of mice (96). The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.